23% of people infected with SARS-CoV-2 between 2021 and 2023 developed long-COVID, and in more than half of them the symptoms persisted for two years.
Avadel’s narcolepsy drug Lumryz misses PDUFA date, still under review at FDA
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
September 13, 2024